Fast-track drug approval in inflammatory bowel diseases

about

Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway.

P2860

Q33638449-6DDC08D0-EC32-4FF8-82B4-61BA87BDB2EB Q46051469-0DE0554B-AFB9-4019-BDE5-70F99728302F

P2860

Fast-track drug approval in inflammatory bowel diseases

Item

http://www.wikidata.org/entity/Q28077510

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Fast-track drug approval in inflammatory bowel diseases

@ast

Fast-track drug approval in inflammatory bowel diseases

@en

Fast-track drug approval in inflammatory bowel diseases

@nl

type

Item

label

Fast-track drug approval in inflammatory bowel diseases

@ast

Fast-track drug approval in inflammatory bowel diseases

@en

Fast-track drug approval in inflammatory bowel diseases

@nl

prefLabel

Fast-track drug approval in inflammatory bowel diseases

@ast

Fast-track drug approval in inflammatory bowel diseases

@en

Fast-track drug approval in inflammatory bowel diseases

@nl

P1476

Fast-track drug approval in inflammatory bowel diseases

@en

P2093

Almpani E

http://www.w3.org/2001/XMLSchema#string

Christodoulou DK

http://www.w3.org/2001/XMLSchema#string

Giagkou E

http://www.w3.org/2001/XMLSchema#string

Katsanos KH

http://www.w3.org/2001/XMLSchema#string

Koutroumpakis E

http://www.w3.org/2001/XMLSchema#string

Malakos Z

http://www.w3.org/2001/XMLSchema#string

Skamnelos A

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation.

Regulatory review of novel therapeutics--comparison of three regulatory agencies.

Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.

Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.

Treat to target: a proposed new paradigm for the management of Crohn's disease.

Will biosimilars gain momentum?

Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.

A comparison of FDA and EMA drug approval: implications for drug development and cost of care.

P304

439-444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4795916

http://www.w3.org/2001/XMLSchema#string

P356

10.20524/AOG.2016.0051

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27708508

http://www.w3.org/2001/XMLSchema#string

P921

drug approval

inflammatory bowel diseases

P932

5049549

http://www.w3.org/2001/XMLSchema#string

Fast-track drug approval in inflammatory bowel diseases

about

P2860

P2860

Fast-track drug approval in inflammatory bowel diseases

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P577

P698

P921

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P577

P698

P921

P932